GTC Biotherapeutics (fka GTCB)

[biopearl]

Flo, Dew and mb, I did see on gov trials site that there was a "trend toward significance" in chronic RA patients BUT in patients with RA of less than 2 years duration that results with MM 093 were statistically significant. Did anyone else see this and what is your take? I would think this finding would engender some serious discussion and will probably be the focus of the paper at the EULR. Higher dose study proceding as noted. There was an unclear statement regarding adverse effects from the "drug" occuring in the placebo group. This is not clear of course. Can anyone clarify? It was interesting to note little board discussion re the Merrimack announcement of April 17th. I was out of the country and am now reviewing older posts with interest. Flo of course right on with info re EULR presentation and press release--thank you! Any speculation as to whether PML might be a potential adverse effect (a la Tysabri)especially in patients already on an immunosuppressant such as MTX. Regards to all, Should be an interesting summer with the release of Atryn and presentation of positive MM093 results. bp